Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kate Simpson

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
European Journal of Cancer (Oxford, England : 1990)|October 14, 2021
Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinomaAnanth Shankar, Tom Kurzawinski, Emma Ross, et al.
Scientific Reports|August 14, 2021
miR-141 mediates recovery from acute kidney injuryLucy J Newbury, Kate Simpson, Usman Khalid, et al.
Pilot and Feasibility Studies|January 8, 2026
Protocol for a feasibility and acceptability trial of Bloom, a co-produced and co-facilitated parent group to enhance the quality of life and well-being of young autistic childrenDawn Adams, Kathryn Ambrose, Rachael Bowen, et al.
Scientific Reports|September 9, 2017
In search of a small molecule agonist of the relaxin receptor RXFP1 for the treatment of liver fibrosisAndrew McBride, Anna M Hoy, Mark J Bamford, et al.
Therapeutic Advances in Chronic Disease|August 21, 2023
Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn's disease cohort with penetrating disease, -ostomies and sarcopeniaSaskia Inniss, Konstantinos C Fragkos, Lisa Whitley, et al.
Inflammatory Bowel Diseases|September 23, 2020
Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's DiseaseMark T Osterman, Kelli L VanDussen, Ilyssa O Gordon, et al.
The New England Journal of Medicine|March 1, 2023
Nicotinamide for Skin-Cancer Chemoprevention in Transplant RecipientsNicholas C Allen, Andrew J Martin, Victoria A Snaidr, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
European Journal of Cancer (Oxford, England : 1990)|October 14, 2021
Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinomaAnanth Shankar, Tom Kurzawinski, Emma Ross, et al.
Scientific Reports|August 14, 2021
miR-141 mediates recovery from acute kidney injuryLucy J Newbury, Kate Simpson, Usman Khalid, et al.
Pilot and Feasibility Studies|January 8, 2026
Protocol for a feasibility and acceptability trial of Bloom, a co-produced and co-facilitated parent group to enhance the quality of life and well-being of young autistic childrenDawn Adams, Kathryn Ambrose, Rachael Bowen, et al.
Scientific Reports|September 9, 2017
In search of a small molecule agonist of the relaxin receptor RXFP1 for the treatment of liver fibrosisAndrew McBride, Anna M Hoy, Mark J Bamford, et al.
Therapeutic Advances in Chronic Disease|August 21, 2023
Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn's disease cohort with penetrating disease, -ostomies and sarcopeniaSaskia Inniss, Konstantinos C Fragkos, Lisa Whitley, et al.
Inflammatory Bowel Diseases|September 23, 2020
Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's DiseaseMark T Osterman, Kelli L VanDussen, Ilyssa O Gordon, et al.
The New England Journal of Medicine|March 1, 2023
Nicotinamide for Skin-Cancer Chemoprevention in Transplant RecipientsNicholas C Allen, Andrew J Martin, Victoria A Snaidr, et al.
Pageof 7